Table 7 DDA-based TB vaccine formulation optimization studies
From: Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines
Lipid(s) and sterol used | Cell line/animal model used | Administration route | Promising liposome formulation | References |
|---|---|---|---|---|
DDA, DDA/Tween 80, DDD/Span 85, DDA/Tween 80/Span 85, DDA/gelatin, DDA/Chol, DDA/Lecithin, DDA/β-Cyclodextrin and DDA/PLGA | C57BL/6 mice | Subcutaneous | DDA/Chol | [126] |
DDA, DOTAP, DC-Chol, DOPE/PC and DOPE/PC/PG | Splenocytes from BALB/c and C57BL/6 mice | Subcutaneous | DDA | [125] |
DDA/DSPC | Splenocytes from C57BL/6 mice | Intramuscular | DDA/DSPC | [18] |
DDA | Splenocytes from BALB/c mice | Subcutaneous | DDA | [6] |
DDA | Human/macrophage cell line THP-1 and splenocytes from BALB/c mice | Intramuscular | DDA | [30] |
DDA | Inguinal lymph nodes or spleens | Subcutaneous | DDA | [128] |
DDA | C57BL6; spleen and lung lymphocytes | Subcutaneous | DDA | [124] |
DDA and DDA/Chol | Splenocytes from C57BL/6 mice and THP-1 cells | Intramuscular | DDA | [52] |
DDA/MMG | Splenocytes from C57BL/6 mice | Subcutaneous | DDA/MMG | [134] |
DDA | BALB/c mice | Intracutaneous | DDA | [122] |
DDA | C57BL6 mice | Subcutaneous | DDA | [129] |
DDA | BALB/c mice | Intracutaneous | DDA | [123] |
DDA | Splenocytes from BALB/c mice | Intramuscular | DDA | [44] |
LAM/PC/Chol/stearyl octaarginine | PBMCs | N/A | LAM/PC/Chol/stearyl octaarginine | [17] |
DDA | DCs | Subcutaneous | DDA | [135] |